BY J.B. HANDLEY September 18, 2017
In the December 2017 issue of the Journal of Inorganic Biochemistry and released online today, Dr. Christopher Shaw and colleagues at the University of British Columbia have established convincing biological evidence linking aluminum adjuvant used in vaccines to autism.
“This is the paper I have been waiting for. This paper reports measurements of cytokines in the brains of animals injected with aluminum adjuvant as neonates. The same cytokines are elevated as in human autism. IL-6 and CCL2/MCP-1 are elevated for example. Male animals are more strongly affected. It’s a perfect match to human autism.”
VANCOUVER, British Columbia — Just two weeks ago, I wrote about a study from France that raised major concerns about aluminum adjuvant used in vaccines. The French study authors wrote: “Concerns about its [aluminum adjuvant’s] safety emerged following recognition of its unexpectedly long-lasting biopersistence within immune cells in some individuals, and reports of chronic fatigue syndrome, cognitive dysfunction, myalgia, dysautonomia and autoimmune/inflammatory features temporally linked to multiple Al [aluminum]-containing vaccine administrations.”
In a nutshell, the French study found that when smaller doses of aluminum adjuvant were consistently injected over a short period of time — like during childhood vaccinations —the aluminum was more likely to end up in the brain, and the French scientists issued a stern warning about the use of aluminum adjuvant in vaccines:
In the context of massive development of vaccine-based strategies worldwide, the present study may suggest that aluminium adjuvant toxicokinetics and safety require reevaluation.
Canadian researchers establish direct link
In the December 2017 issue of the Journal of Inorganic Biochemistry and released online today, Dr. Christopher Shaw and colleagues have established convincing biological evidence linking aluminum adjuvant to autism. The study’s title alone should cause concern for parents everywhere:
Subcutaneous injections of aluminum at vaccine adjuvant levels activate innate immune genes in mouse brain that are homologous with biomarkers of autism
As the study authors state:
“It thus appears that Al [aluminum adjuvant] triggered innate immune system activation and altered cholinergic activity in male mice, observations which are consistent with those in autism. Female mice were less susceptible to Al exposure as only the expression levels of NF-κB inhibitor and TNFA were altered. Regional patterns of gene expression alterations also exhibited gender differences, as frontal cortex was the most affected area in males and cerebellum in females. Thus, Al adjuvant promotes brain inflammation and males appear to be more susceptible to Al′s toxic effects.”
It’s critical to note that the researchers found gender differences in how the mice responded, with male mice showing higher susceptibility, which is consistent with what we are seeing in autism: roughly 80% of the cases are boys.